Characterization of Bronchodilator Response in Children With Bronchiolitis Using Phenotypic and Genotypic Features

PHASE3RecruitingINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

July 8, 2022

Primary Completion Date

December 31, 2029

Study Completion Date

December 31, 2030

Conditions
BronchiolitisBronchodilator Agents
Interventions
DRUG

Albuterol Sulfate, 2.5 Mg/3 mL (0.083%) Inhalation Solution

Children with bronchiolitis will be randomized to an intervention arm to be administered as a nebulization (albuterol sulfate 2.5mg/ 3mL inhalation solution). The intervention drug will be placed in a sealed manila envelope, randomized in advance by a Nemours Investigational Drug Pharmacist, and stored in the ED pyxis.

DRUG

Sodium Chloride 0.9% Inhl 3Ml

Children with bronchiolitis will be randomized to an intervention arm to be administered as a nebulization (sodium chloride 0.9% 3mL inhalation solution). The intervention drug will be placed in a sealed manila envelope, randomized in advance by a Nemours Investigational Drug Pharmacist, and stored in the ED pyxis.

Trial Locations (1)

32827

RECRUITING

Nemours Children's Health, Orlando

All Listed Sponsors
lead

Nemours Children's Clinic

OTHER